Lysocardiolipin acyltransferase 1 (LCLAT1)

Lysocardiolipin acyltransferase 1 (LCLAT1) is an enzyme located in the endoplasmic reticulum and mitochondria, responsible for catalyzing the reacylation of monolysocardiolipin (MLCL) to cardiolipin, an essential mitochondrial phospholipid vital for mitochondrial structure and bioenergetic function[1][3][4][5]. LCLAT1 plays a crucial role in determining the acyl-chain composition of cardiolipin and phosphatidylinositols, thereby influencing mitochondrial membrane integrity, signaling, and cellular metabolism[1][2]. Dysregulation or overexpression of LCLAT1 is implicated in cardiovascular, metabolic, and neurodegenerative diseases, due to its connection to pathological cardiolipin remodeling, oxidative stress, and bioenergetic failure[1][2][3]. LCLAT1 is regarded as a potential therapeutic target in diseases characterized by mitochondrial dysfunction and aberrant lipid remodeling, but no approved drugs currently modulate its activity directly[2].

Other names

ALCAT1AGPAT8LYCATLPLAT61-acylglycerol-3-phosphate O-acyltransferase 81-AGP acyltransferase 8Lysophospholipid acyltransferase 6Acyl-CoA:lysocardiolipin acyltransferase 1FLJ37965HSRG1849UNQ1849/PRO3579

Not directly defined due to a lack of clinically validated inhibitors. In theory: Inhibitors of LCLAT1 would block pathologic cardiolipin remodeling, potentially restoring mitochondrial function and reducing oxidative stress and related pathology[1][2].